Recruiting

Effects of GLP-1 RAs on Human Lactation Outcomes

Lead sponsor

University of Colorado, Denver

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•Female

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07720414

Org study ID26-1234

Timeline

Milestones

Study first posted2026-07-22actual

Last update posted2026-07-22actual

Study start2026-07estimated (month precision)

Primary completion2028-06estimated (month precision)

Study completion2028-06estimated (month precision)

Assets

Investigational agents

Semaglutide Tirzepatide

Who this study enrolls

Obesity / overweight

Who can enroll

SexFemale

Healthy volunteersAccepted

Sampling methodNon probability sample

Study population text

Breastfeeding mothers willing to attend study study visits in Aurora, CO.

Inclusion criteria

•Breastfeeding mothers of single or multiple infants.

•Milk removal at least 4x daily

•Eligible for a GLP-1 RA administered subcutaneously (oral GLP-1 RAs contain absorption enhancers, which may drive accumulation in milk)

•Access to a breastpump, if needed for maintaining breastfeeding behaviors.

•Willingness to provide 1-3 oz of breastmilk per study visit.

•Willingness to track and report body weight daily.

•Willingness to maintain breastfeeding behaviors for the duration of the study.

Exclusion criteria

•Currently taking GLP-1 RA medication or other weight loss medication

•Induced lactation, due to unknowns regarding the durability of the mammary gland's milk production after exogenous stimulation.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.